Venetoclax, an orally administered BH3-mimetic, specifically inhibits the anti-apoptotic protein BCL-2, a key regulator that prevents programmed cell death in CLL cells. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.